Mineralocorticoid receptor (MR) blockers (MRBs) are expected to exert antihypertensive and organ-protective effects in MR-associated hypertension caused by lifestyle factors such as excessive salt intake, DM, and obesity [13]. This evidence concerns the gene NR3C2 and diabetes mellitus.